Research Topics
Species | Thomas GajewskiSummaryAffiliation: University of Chicago Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironmentThomas F Gajewski
University of Chicago, United States Electronic address
Curr Opin Immunol 25:268-76. 2013..New therapeutic interventions are being guided by these observations, and preliminary clinical success is validating this working model...
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)Thomas F Gajewski
The University of Chicago, Section of Hematology Oncology, 5841 S, Maryland Ave, MC2115, Chicago, IL 60637, USA
J Transl Med 10:246. 2012..As farnesylated proteins are also important for T cell activation, measurement of effects on T cell function was also pursued...- Innate immune sensing of cancer: clues from an identified role for type I IFNsThomas F Gajewski
Department of Pathology, The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
Cancer Immunol Immunother 61:1343-7. 2012..Elucidating further these innate immune mechanisms should provide new insights into cancer immunotherapy... - Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto
Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
J Transl Med 10:83. 2012.... - Defining the critical hurdles in cancer immunotherapyBernard A Fox
Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
J Transl Med 9:214. 2011..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer... - The immune score as a new possible approach for the classification of cancerJerome Galon
INSERM, U872, Laboratory of Integrative Cancer Immunology, 15 Rue de l Ecole de Medecine F 75006 Paris, France
J Transl Med 10:1. 2012.... - SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discoveryDavide Bedognetti
Society for Immunotherapy of Cancer, Milwaukee, WI, USA
J Transl Med 9:155. 2011..This organized collection of the most useful references, online resources and tools serves as a compass to guide discovery of biomarkers essential to advancing novel cancer immunotherapies... - Review of the 25th annual scientific meeting of the International Society for Biological Therapy of CancerJames M Balwit
Society for Immunotherapy of Cancer, Milwaukee, WI, USA
J Transl Med 9:60. 2011.... 
Integrating IL-12 into therapeutic cancer vaccinesThomas F Gajewski
Departments of Pathology and Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Ave, MC2115, Chicago, IL 60637, USA
Cancer Chemother Biol Response Modif 20:343-9. 2002- The expanding universe of regulatory T cell subsets in cancerThomas F Gajewski
University of Chicago, Chicago, IL 60637, USA
Immunity 27:185-7. 2007..In this issue of Immunity, Peng et al. (2007) add to this list by describing tumor-infiltrating gammadelta T cells that have regulatory function... - Immune resistance orchestrated by the tumor microenvironmentThomas F Gajewski
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
Immunol Rev 213:131-45. 2006..Identification of these downstream processes points to new therapeutic targets that should be manipulated to facilitate the effector phase of anti-tumor immune responses in concert with vaccination or T-cell adoptive transfer... - Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironmentThomas F Gajewski
Department of Pathology, University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 12:2326s-2330s. 2006..Importantly, each of these targets is amenable to clinical manipulation. Clinical translation of these approaches to counter negative regulation of antitumor immunity should receive high priority... - Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanomaThomas F Gajewski
Department of Medicine, University of Chicago, IL 60637, USA
Clin Cancer Res 11:7861-5. 2005..We postulated that the addition of O(6) benzylguanine (O(6)BG), a potent inactivator of AGT, would improve the clinical response to BCNU in melanoma... - Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1Thomas F Gajewski
Department of Pathology, Section of Hematology Oncology, The University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA
Curr Opin Investig Drugs 5:1279-83. 2004..Blockade of these molecules may increase the efficacy of tumor-specific T-cell therapies in cancer patients... - Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccinesKatharina Tschoep
Department of Pathology, Section of Hematology Oncology, University of Chicago, Illinois, USA
J Leukoc Biol 74:69-80. 2003..Our results suggest that the functions thought to contribute to optimal T cell priming are not coexpressed by the same DC population and that immature and mature DC likely possess distinct CD40-mediated signaling events... - Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironmentThomas F Gajewski
Departments of Pathology and Medicine, University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 13:5256-61. 2007..Recognition of these evasion mechanisms has pointed toward new therapeutic approaches for cancer immunotherapy... - Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironmentThomas F Gajewski
The University of Chicago, Chicago, IL 60636, USA
Curr Opin Immunol 23:286-92. 2011..But in addition, characterization of these subsets may pave the way for catering therapeutic interventions toward the biologic features of the tumor in individual patients... - Molecular profiling of melanoma and the evolution of patient-specific therapyThomas F Gajewski
Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
Semin Oncol 38:236-42. 2011.... - Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapyThomas F Gajewski
University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
Cancer J 16:399-403. 2010.... - Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12T F Gajewski
Department of Pathology, The University of Chicago, Illinois 60637, USA
Clin Cancer Res 7:895s-901s. 2001..Outgrowth of antigen-negative tumors argues for the future development of polyepitope vaccines... - Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphataseT F Gajewski
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
J Immunol 166:3900-7. 2001..Thus, the biochemical mechanism explaining the differential inhibitory effect of CTLA-4 on naive and primed CD8(+) T cells remains unclear... - Immune suppression in the tumor microenvironmentThomas F Gajewski
Department of Pathology and Department of Medicine University of Chicago, Chicago, IL 60637, USA
J Immunother 29:233-40. 2006.... - Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient miceA K Kacha
Department of Pathology and the Committee on Immunology, Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
J Immunol 165:6024-8. 2000..Rejection was accompanied by augmented tumor-specific IFN-gamma production and CTL activity. These results suggest that pharmacologic inhibition of Stat6 signaling could potentiate anti-tumor immunity in vivo... - CD28 is not required for c-Jun N-terminal kinase activation in T cellsF V Rivas
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
J Immunol 167:3123-8. 2001..Thus, CD28 coligation is not necessary, and stimulation through the TCR is sufficient, for JNK activation in normal murine T cells. The concept that JNK mediates the costimulatory function of CD28 needs to be reconsidered... - B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28F Fallarino
Department of Pathology, The University of Chicago, Chicago, Illinois 60637, USA
J Exp Med 188:205-10. 1998..Thus, CTLA4 can potently inhibit T cell activation in the absence of CD28, indicating that antagonism of a TCR-mediated signal is sufficient to explain the inhibitory effect of CTLA4... - Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1AM A Markiewicz
Department of Pathology, University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA
Int Immunol 13:625-32. 2001..A broadened CTL response may help eliminate outgrowth of antigen-negative tumor variants... - B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cellsP E Fields
Department of Pathology, University of Chicago, IL 60637, USA
J Immunol 161:5268-75. 1998..2. Further, our results indicate that the activation state of the responding T cell may influence the efficiency with which the T cell can respond to a costimulatory signal provided by either B7.1 or B7.2... - Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1F Fallarino
Department of Pathology, Department of Medicine, Section of Hematology Oncology, University of Chicago, IL 60637, USA
J Immunol 163:4109-13. 1999..Lack of cytolytic function correlated with a failure to up-regulate serine esterase activity. Thus, IFN-mediated signaling on host cells is required for the development of antitumor lytic effector cells... - Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago ExperienceA S Artz
University of Chicago Hospitals, Chicago, IL 60637 1470, USA
Bone Marrow Transplant 35:253-60. 2005..002). NST leads to durable responses in a minority of metastatic RCC patients. Appropriate patient selection is paramount. Anemia and decreased performance status may enable risk stratification... - Expression and function of CTLA-4 in Th1 and Th2 cellsM L Alegre
Howard Hughes Medical Institute, University of Chicago, IL 60637, USA
J Immunol 161:3347-56. 1998..We conclude that CTLA-4 can function to suppress the production of cytokines produced by both Th1 and Th2 cells... - Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomasXavier Poiré
Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
Leuk Lymphoma 51:1241-50. 2010..Post-ASCT immunomodulation with rituximab, IL-2, and GM-CSF was feasible and safe, but not all patients were able to continue on to post-ASCT immunotherapy... - Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cellsH Harlin
Department of Pathology, The University of Chicago, IL 60637, USA
Bone Marrow Transplant 33:491-7. 2004..Our results support the hypothesis that the antitumor effects of NST may be mediated by IFN-gamma-producing CD8+ T cells, and indicate that isolation of putative tumor antigen-specific T cells, ideally, should be pursued around day +180... - Antigen-specific blockade of T cells in vivo using dimeric MHC peptideS M O'Herrin
The Ben May Institute for Cancer Research, Department of Pathology, University of Chicago, Chicago, IL 60637, USA
J Immunol 167:2555-60. 2001..The prolonged Ag-specific suppression of expansion and/or effector function of cognate T cells in vivo suggests that soluble MHC dimers may be a means of inducing sustained Ag-specific T cell unresponsiveness in vivo... - Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cellsR Q Cron
University of Chicago, Ben May Institute, Department of Pathology, IL 60637
J Immunol 142:3754-62. 1989..Finally, activated CD3+, CD4-,CD8-,TCR-gamma delta+ splenocytes were also capable of producing IL-2, IL-3, IFN-gamma, and TNF when stimulated in vitro with anti-CD3-epsilon mAb... - Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanomaM Aklilu
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
Ann Oncol 15:1109-14. 2004.... - CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cellsLuciana L Molinero
Department of Medicine, University of Chicago, Chicago, IL 60637, USA
J Immunol 182:6736-43. 2009..These data suggest a modified model of nTreg development in which TCR-CBM-dependent signals are essential to commit immature thymocytes to the nTreg lineage... - The p815 mastocytoma tumor modelT F Gajewski
The University of Chicago, Chicago, Illinois, USA
Curr Protoc Immunol . 2001.... - Peripheral survival of naïve CD8+ T cellsI E Brown
Department of Pathology, University of Chicago, 5841 S. Maryland Ave, Chicago, IL 60637, USA
Apoptosis 10:5-11. 2005..We also discuss associations between survival and homeostasis-driven proliferation, and highlight the gaps in our knowledge of these critical processes... - A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancerJerome D Winegarden
The Department of Medicine, Section of Hematology and Oncology, University of Chicago Medical Center, University of Chicago Cancer Center and the Phase II Network, 5841 S Maryland Avenue MC2115, Chicago, IL 60637, USA
Lung Cancer 39:191-6. 2003..The predominance of myalgia in the absence of elevated serum cytokines suggests a non-inflammatory etiology of this toxicity... - Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progressionYuru Meng
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
J Immunol 177:1981-7. 2006..The fact that granule induction can be achieved through TCR and CD28 ligation has implications for restoring lytic effector function in the context of antitumor immunity... - Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejectionIan E Brown
Department of Pathology and Department of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
J Immunol 177:4521-9. 2006..Taken together, our data suggest that a major mechanism by which homeostatic proliferation supports tumor rejection is by maintaining and/or re-establishing T cell responsiveness... - Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cellsCandace M Cham
Committee on Cancer Biology, The University of Chicago, Chicago, IL 60637, USA
Eur J Immunol 38:2438-50. 2008.... - Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cellsKwang Woo Hwang
Department of Medicine and Committee in Immunology, University of Chicago, Chicago, IL 60637, USA
J Immunol 169:633-7. 2002..Furthermore, CTLA-4(+/+) T cells that had encountered 7M-expressing tumors in vivo acquired defects in cytokine production and cytotoxicity. Thus, deliberate ligation of CTLA-4 in vivo potently inhibits allogeneic T cell responses... - Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional levelReinhard E Marks
Department of Pathology, University of Chicago, IL, USA
Blood 110:1982-8. 2007..These results indicate that FTIs inhibit T-cell activation at the posttranscriptional level and also suggest that they may have potential as novel immunosuppressive agents... - Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastasesPing Yu
Committee on Immunology and Department of Pathology, University of Chicago, Chicago, IL 60637, USA
J Immunol 179:1960-8. 2007..Therefore, targeting the primary tumor with Ad-LIGHT before surgical excision is a new strategy to elicit better immune response for the eradication of spontaneous metastases... - Report on the ISBTC mini-symposium on biologic effects of targeted therapeuticsMichael B Atkins
Beth Israel Deaconess Medical Center, Boston, MA, USA
J Immunother 30:577-90. 2007.... - Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activityBrian I Rini
Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, U.S.A
J Immunother (1997) 25:269-77. 2002.... - An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cellsYuanyuan Zha
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
Cell Immunol 247:95-102. 2007..Our results indicate that introduction of dominant negative Cbl can potentiate activation of post-thymic CD4+ T cells, which argues for development of strategies to interfere with Cbl function as a method of immunopotentiation... - Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanomaJustin Kline
Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 14:3156-67. 2008..To investigate the antitumor efficacy of T-cell anergy reversal through homeostatic proliferation and regulatory T-cell (Treg) depletion in a clinically relevant murine adoptive immunotherapy model... - Production of TH1 and TH2 cell lines and clonesFRANK W FITCH
University of Chicago, Chicago, Illinois, USA
Curr Protoc Immunol . 2006..Support protocols describe a micromanipulation method for cloning T cells and a roadmap for using protocols published elsewhere in this series to assess cytokine production by T cell clones and lines... - Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cellsMichael T Spiotto
Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
Immunity 17:737-47. 2002..Thus, tumor antigens expressed at levels sufficient for crosspresentation by bone marrow-derived stromal cells may overcome immunological "ignorance" to solid tumors... - Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cellsYuanyuan Zha
Department of Pathology and Department of Medicine, University of Chicago, Chicago, IL 60637, USA
J Immunol Methods 331:94-102. 2008..This technology should be broadly applicable for studies of T cell-specific gene deletion to gain understanding of function in the post-thymic T cell compartment... - Update on vaccines for solid tumorsThomas F Gajewski
University of Chicago, Chicago, IL 60637, USA
Clin Adv Hematol Oncol 2:158-9. 2004 - B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanismXingluo Liu
Department of Pathology, Ohio State University Medical Center, Columbus, OH 43210, USA
J Exp Med 197:1721-30. 2003..Our results demonstrate a novel pathway for B7DC to promote tumor immunity and may reconcile the apparently contradictory findings on the function of B7DC... - Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xLMary A Markiewicz
Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
Eur J Immunol 33:2917-26. 2003..These results suggest that, in the absence of a survival signal provided by engagement of host MHC/self peptide complexes, CD8(+) T cells die via a Fas-dependent, mitochondria-independent pathway... - Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapyChristian Blank
Department of Hematology and Oncology, University of Regensburg, Franz Josef Strauss Allee 11, 93042 Regensburg, Germany
Cancer Immunol Immunother 54:307-14. 2005..This review discusses the currently available data concerning negative T-cell regulation via PD-1, the blockade of PD-L1/PD-1 interactions, and the implications for adoptive T-cell therapies... - Negative regulation of T-cell function by PD-1Yuan Yuan Zha
University of Chicago, Department of Pathology, Section of Hematology/Oncology, Chicago, IL 60637, USA
Crit Rev Immunol 24:229-37. 2004..This review summarizes data regarding PD-1 and related negative regulatory receptors, focusing on implications for potentiating antitumor immunity in vivo... - Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignanciesTodd M Zimmerman
Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
J Clin Oncol 22:4816-22. 2004..Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, has activity in hematologic malignancies, but the dose required to achieve the proposed biologic end point, inhibition of farnesylation, is unknown... - Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cellsChristian Blank
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
J Immunol 171:4574-81. 2003..Our results are consistent with a model in which absence of PD-1 leads to greater negative selection of strongly interacting DP cells as well as increased emergence of DN alphabeta peripheral T cells... - Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanomaAmy C Peterson
Department of Pathology, University of Chicago, IL 60637, USA
J Clin Oncol 21:2342-8. 2003..046). CONCLUSION: This immunization approach may be more straightforward than dendritic cell strategies and seems to have clinical activity that can be correlated to a biologic end point... - Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cellsKelly Blaine
Committee on Cancer Biology and Department of Pathology, University of Chicago, IL 60637, USA
Proc Natl Acad Sci U S A 101:9351-6. 2004.... - PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cellsChristian Blank
Department of Pathology, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA
Cancer Res 64:1140-5. 2004..Our results support interfering with PD-L1/PD-1 interactions to augment the effector function of tumor antigen-specific CD8(+) T cells in the tumor microenvironment... - Actin cytoskeleton regulates calcium dynamics and NFAT nuclear durationFabiola V Rivas
Department of Pathology, The University of Chicago, Chicago, Illinois 60637, USA
Mol Cell Biol 24:1628-39. 2004..Our results imply a novel role for the actin cytoskeleton in modulating the duration of Ca(2+)-NFAT signaling and indicate that actin dynamics regulate features of T-cell activation downstream of receptor clustering... - ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivoChristian Blank
Department of Pathology, Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
J Immunol 174:3416-20. 2005..Our results suggest that ICAM-1 contributes to but is not absolutely required for CD8+ T cell-mediated tumor rejection in vivo and dominantly acts at the level of priming rather than the effector phase of the antitumor immune response... - Metabolic mechanisms of tumor resistance to T cell effector functionCandace M Cham
Department of Pathology, Department of Medicine, and the Ben May Institute, University of Chicago, Chicago, IL 60637, USA
Immunol Res 31:107-18. 2005..These observations provide a conceptual framework for modulating metabolic features of the T cell-tumor interaction, toward the end of promoting more effective immune-mediated tumor destruction in vivo... - A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinomaAmy C Peterson
Department of Medicine, Section of Hematology/Oncology, The University of Chicago, USA
Invest New Drugs 24:141-9. 2006..CONCLUSIONS: The addition of Bryostatin-1 to IL-2 was well tolerated, but the overall response rate was low (3.2%), indicating that further studies with this combination are not warranted... - Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapySimona Velicu
Division of Neurosurgery, The University of Chicago, Pritzker School of Medicine, 5841 S. Maryland Ave-MC 3026, Chicago, IL 60637, USA
J Neuroimmunol 174:74-81. 2006.... - Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitroChristian Blank
Department of Hematology and Oncology, University of Regensburg, Regensburg, Germany
Int J Cancer 119:317-27. 2006..In summary, our data suggest that PD-L1/PD-1 interactions negatively regulate T cell effector functions predominantly in the absence of exogenous cytokine support, indicating an important role for this pathway in tumor evasion... - Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascitesHelena Harlin
Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Ave, MC2115, Chicago, IL 60637, USA
Cancer Immunol Immunother 55:1185-97. 2006.... - Temozolomide for melanoma: new toxicities and new opportunitiesThomas F Gajewski
J Clin Oncol 22:580-1. 2004 - Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts
Virginia Commonwealth University, Richmond, Virgina 23298 0037, USA
J Immunother 29:95-101. 2006..The combination of g209-2M and low-dose IL-2 is safe and tolerable but inactive against advanced melanoma. Absence of evidence of immunization raises concerns for peptide-based immunization strategies with concurrent IL-2... - Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cellsJames P O'Keefe
Committee on Cancer Biology, University of Chicago, IL 60637, USA
J Immunol 175:5581-5. 2005..Together, our results indicate that the formation of a cSMAC is not required for cytolytic activity in CD8+ effector T cells... - T cell development and function in CrkL-deficient miceAmy C Peterson
Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
Eur J Immunol 33:2687-95. 2003..Our results indicate that CrkL is not absolutely required for T cell development or function, and argue against it being an essential component of a negative regulatory pathway in TCR signaling... - Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cellsCandace M Cham
Committee on Cancer Biology, Department of Pathology, University of Chicago, Chicago, IL 60637, USA
J Immunol 174:4670-7. 2005.... - Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical resultsBrian I Rini
University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
J Clin Oncol 20:2017-24. 2002..To evaluate the feasibility and safety of nonmyeloablative allogeneic stem-cell transplantation in patients with metastatic renal cell cancer (RCC) and to evaluate efficacy with respect to engraftment and tumor regression... - Molecular regulation of T-cell anergyYan Zheng
University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
EMBO Rep 9:50-5. 2008..A model is emerging for how these factors are regulated to control T-cell responsiveness... - Diagnosis and treatment of mycoplasma-contaminated cell culturesHelena Harlin
University of Chicago, Chicago, Illinois, USA
Curr Protoc Cytom . 2008..This appendix describes how to test for mycoplasma contamination, and also presents methods for antibiotic treatment of infected cultures... - Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytesReinhard E Marks
Department of Pathology, Department of Medicine Section of Hematology/Oncology, The Ben May Institute for Cancer Research, University of Chicago, Chicago, IL 60637, USA
Biochem Biophys Res Commun 312:691-6. 2003.... - Lymphoma-infiltrating immune cellsThomas F Gajewski
N Engl J Med 352:724-5; author reply 724-5. 2005 - Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Clin Cancer Res 12:2291s-2296s. 2006.... - Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanomaAmy C Peterson
Department of Medicine, Section of Hematology/Oncology, University of Chicago Cancer Research Center, Chicago, Illinois, USA
Clin Cancer Res 10:4048-54. 2004..Although the modest clinical activity and potential effects on tumor vascularity may support additional exploration of VEGF as a target in melanoma, effects from steroid premedication limit further investigation of this agent... - T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alphaYuanyuan Zha
Department of Pathology, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois 60637, USA
Nat Immunol 7:1166-73. 2006..Our data support a causal function for excess DGK activity and defective Ras signaling in T cell anergy... - On the TRAIL toward death receptor-based cancer therapeuticsThomas F Gajewski
J Clin Oncol 25:1305-7. 2007 - Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiationCandace M Cham
Committee on Cancer Biology, University of Chicago, Chicago, Illinois 60637, USA
J Biol Chem 278:17044-52. 2003.... - Diagnosis and treatment of Mycoplasma-contaminated cell culturesHelena Harlin
University of Chicago, Chicago, Illinois, USA
Curr Protoc Microbiol . 2006..This appendix describes how to test for mycoplasma contamination, and also presents methods for antibiotic treatment of infected cultures... - Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over timeMilica Medved
Department of Radiology, The University of Chicago, Chicago, Illinois, USA
J Magn Reson Imaging 20:122-8. 2004..Use of this method as a pharmacodynamic marker should be further investigated...
Research Grants
- T Cell Responsiveness and Homeostasis in Anti-TumorThomas Gajewski; Fiscal Year: 2007..T cell transduction and tumor transfectants will be examined using factors identified to be useful from the TCR Tg model and mechanisms of improved tumor control will be dissected. ..
- Countering immune resistance in the melanoma tumor microenvironmentThomas F Gajewski; Fiscal Year: 2010....
- Countering immune resistance in the melanoma tumor microenvironmentThomas Gajewski; Fiscal Year: 2009....
- T Cell Responsiveness and Homeostasis in Anti-TumorThomas F Gajewski; Fiscal Year: 2010..T cell transduction and tumor transfectants will be examined using factors identified to be useful from the TCR Tg model and mechanisms of improved tumor control will be dissected. ..
- Countering immune resistance in the melanoma tumor microenvironmentThomas Gajewski; Fiscal Year: 2007....
- Multi-Peptide/IL 12 Melanoma VaccineThomas Gajewski; Fiscal Year: 2006..Understanding these mechanisms will illuminate the next level of intervention to develop to increase the clinical response to the immunotherapy of melanoma. ..
- Technologies To Block Gene Expression in Normal T CellsThomas Gajewski; Fiscal Year: 2003..abstract_text> ..
- Biochemical/Molecular Changes Upon Naive T Cell PrimingThomas Gajewski; Fiscal Year: 2005....
- Molecular Dissection of T Cell AnergyThomas Gajewski; Fiscal Year: 2005..Ultimately, a complete understanding of the anergic state on the molecular level should guide the development of novel pharmacologic therapies to promote or reverse peripheral tolerance in vivo. ..
- DGK in T Cell Regulation and ToleranceThomas F Gajewski; Fiscal Year: 2010..Ti U,0 ._0 ... ur tow 5a' c' OUP O-0 N-0 0-0 V,12 oar aux. :E, -'1 .., (gyp afl' coo COD m='(Dm o03-' _=c 3m03 l17 CDG'O COB 111 ..